Get started

BCRX

BCRX - Different this time? I propose that there will be no further rejection from .382 after the one we have just seen (in green rectangle) which has been used to form a support This support is something that has been lacking in all the past jumps in price, making me think that this time will be very different Another idea that supports this is the indecision shown on the Gaussian Channel indicator, price is within a relatively tight range, these ranges which often are made to be broken
NASDAQ:BCRX
by Bixley
A Great Risk Reward Opportunity!Hi everyone, Yurii Domaranskyi here. Let's take a look at the chart: 1. Price levels are working good here 2. Globally and locally uptrend 3. The level confirmed by FB 4. All-time high 5. enough room for 1 to 5.1 r/r 6. The price came from below 7. Report on FEBRUARY 23 8. A near test what is bad for short but it stoped below the level 9. No news for the last 10 days Potential risk/reward ratio = 1 to 5.1 meaning that potential risk 100$ with the possibility to make 510$ If it does make sense to you, press a thumb up! 👍
NASDAQ:BCRXShort
by unfair_advantage
$BCRX retrospective lookRetrospective look at $BCRX: 1. Gap down to lower low aligning with oversold signal on RSI (Blue Circle). 2. Continued downtrend forming Descending Triangle (Pink Dashed) following hypotenuse resistance line and flat support line. 3. Double bottom then forms (Green Box & Dotted Line and Orange Arrow) within the converging trendlines. 4. Simultaneous bullish signal on the RSI indicator (Blue Dotted Line). 5. Breakout over resistance trendline with large volume (Blue Volume Circle) 6. RR 1.2:1 take profit could have captured initial move (Long position). Easier to spot now it's happened! Hope this will add to my (and potentially others) knowledge/experience. Any comments appreciated *Not financial advice*
NASDAQ:BCRX
by Angus_Ed
Short opportunity!Buy put 12, April 16 I always try to present the charts in a simple comprehensive format to prevent any confusion. This is just my technical view, neither a fundamental comment nor a recommendation to trade..! Please review my track record and calculate the odds for yourself..! You’re likes and comments encourage me to continue this. Stay tuned great live stream and quality content videos coming soon..! Option trading exposes you to a high risk of losing your capital, never invested in any idea more than what you can afford to lose(5%).
NASDAQ:BCRXShort
by Moshkelgosha
10
BCRX Ascending TriangleBCRX is trading inside a perfect ascending triangle pattern. - BioCryst annnounced this week that the company will host a virtual R&D day on Monday, March 22, 2021 from 9:00 am to 11:00 am ET. - As with many catalyst and events, this could be a "sell the news" and we could see the price sell off on Monday, as the stock already saw a cool 5% gain on Friday in anticipation for the meeting. -On the 30min timeframe, it has broken through a small bearish channel, and will likely retest main support. -will be looking for a long entry if it dips down to bottom support What do you guys think will happen this week?
NASDAQ:BCRXLong
by Lilbuddadude
3
BCRX may start an uptrendAfter a bit of correction and going down to sub $9 last week, buy side was more powerful Friday afternoon, and the SP climbed above $9.50... $10 is a first level resistance point, but once it is achieved, we can expect the SP to run towards $11.80... Support would be around $8.80 but considering the earnings was moved 2 weeks earlier (which may be a good sign), Factor D news, EU Orladeyo approval and upcoming Q1 earnings, the stock is believed to be in a positive momentum... My analysis are not investment advice. Always do your own DD and take your own decisions.
NASDAQ:BCRXLong
by StockNudge
3
CDXC: Small Float Biopharma with BIG Potential $20After basing for many years, CDXC is showing signs of awakening. Stocks are being accumulated but not aggressively. It's one of few bio stocks with insider buying at the current price. The co is likely on track doing $200 mil revenue in 2 or 3 years, 10X of the 200 mil revenue = 2 bil market cap, with about 62 mil shares O/S. Potentially huge valuation creation. Backed by smart biopharma investors with a tiny float (56% controlled by 20 investors). Their product is patented with an 80% gross margin. It is however a stock for patient investors, not fly by the night type of stocks. It is in my Long Term portfolio.
NASDAQ:CDXCLong
by Jonas99
COVID-19 TREATMENTA company that designs and develops novel, oral and small-molecule medicines. Its drug candidates include Berotralstat, BCX9930, BCX9250, RAPIVAB, ALPIVAB, RAPIACTA, PERAMIFLU, Galidesivir and Mundesine. anticipates two regulatory approvals for berotralstat in 2020, Even more impressive, that BCRX will likely get a significant near-term boost from the success of GILD's remdesivir in the treatment of COVID-19. it will help us a lot to conquer against the PANDEMIC. let the BULLS trend here!
NASDAQ:BCRXLong
by lyriccal12
BIOCRYST PHARMACEUTICALS INC. - BCRX Shaping-Up After breaking ‘top-side’ two (2) weeks ago, shares of BioCryst Pharmaceuticals Inc. (BCRX) continue to digest and consolidate the recent run into higher ground in a constructive manner. As we can observe from the Daily chart above, BCRX appears to be building-out a Flag pattern that both investors/traders may want to monitor in the days/weeks ahead. Nonetheless, the action remains technically favorable, whereby BCRX finds itself in a decent posture and readers may want to put BCRX front-and-center on their radars for further monitoring.
NASDAQ:BCRX
by CryptoPulses
THE WEEK AHEAD: EARNINGS AND A PERSISTENTLY LOW VIXIf you're going to play anything next week premium selling wise, it's going to be in earnings, because that's all that's really out there volatility-wise. The VIX remains persistently low here, and running a screen for exchange-traded funds with >70% implied volatility rank, and >35% implied volatility yields absolutely nothing. Here's what showed up on my radar -- some sketchy ADR action (WUBA), a little bit of frisky biopharm (BCRX), and some beaten-down brick-and-mortar retail (M, SHLD, JCP): WUBA (99/56) (Online Retail): It's scheduled to announce earnings on Thursday (2/23) (Short strangle/iron condor). BCRX (98/287) (Biopharm): Earnings Monday (2/27) Before Market Open. (Short puts, short straddle). This is biopharm, which -- in itself -- should serve as a warning. You may want to do a bit more due diligence on this one than you would ordinarily, since they can explode, but also implode. DKS (98/48) (Sporting Goods/Retail): Earnings are three weeks out, but I thought I'd put it out there since it's nearly ripe for play implied volatility rank/implied volatility wise. (Short strangle, iron condor). M (96/49) (Department Store Retail): Earnings Tuesday (2/21) Before Market Open. Because we have a long holiday weekend here, with the markets being closed on Monday, I've probably missed an opp to play this one unless there is high vol afterglow post earnings. (Short strangle, iron condor). SHLD (93/127) (Department Store Retail): I don't see that this has earnings up, but it's in the process of imploding. (Short puts, short straddle). BBY (93/47) (Retail): Earnings 3/1 Before Market Open. We're still a ways out from earnings, so like DKS, nearly ripe ... . (Short strangle, iron condor). HTZ (92/73) (Car Rental): Earnings 2/27 (Monday) After Market Close. Another one that's ripe right now. (Short strangle, iron condor). JCP (88/65) (Department Store/Retail): Earnings Friday (2/24) Before Market Open. Another beaten down brick and mortar retail issue. (Short puts, short straddle). OCN (85/70) (Financial): Earnings on 2/22 (Wednesday) After Market Close. (Short puts,short straddle).
W
by NaughtyPines
2